Supplementary Table 1 Characteristics of Cohort Studies on Body Mass Index and Second

Supplementary Table 1 Characteristics of cohort studies on body mass index and second primary cancers

Source
(Study) / Location/
Recruitment Period / No. of
Participants (Ethnic Origin, %) / Mean Age, y / Mean Follow-up, y / First Primary Tumor Characteristics (%)a / First Primary Tumor Treatment (%) / Second Primary Cancer Siteb
(No. of Cases) / BMI Assessment / Minimal Time between the two Diagnosesc
Dignam, 2003
(NSABP B-14 trial) / United States,
1982-1988 / 3385
(White, 85.5; Black, 4.8; Other/unknown, 9.6) / 55d / 14 / Stage: early (100)
LN: - (100)
ER: + (100)
PR: na / Surgery (100)
Tamoxifen (64.9) / Contralateral Breast (193; premenopausal; postmenopausal) / At baseline,
original study data form, height and weight measuredd / Not stated
Endometrial (51)
Otherse (232)
Li,2003 / United States, 1983-1992 / 1285
(na) / 38 / 9 / Stage: I (37.5), II (51), III (8.7), IV (3.4)
LN: na
ER: + (59), - (40)
PR: + (60), - (39) / Chemotherapy (71.5)
Radiation (56.8)
Tamoxifen (38.3) / Contralateral Breast (77) / At baseline,
face to face interview, height and weight self-reported /  6 months,
opposite breast,
invasive
Dignam, 2006
(NSABP B-13, B-19, B-23 trials) / United States,
1981-1998 / 4077
(White, 86.3; Black, 7.3; Other/unknown, 6.4) / 48d / 14d / Stage: na
Size: 2 cm (59.7), 2-4 cm (34.2), 4.1 cm (6.1)
LN: - (100)
ER: - (100)
PR: na / Surgery (na)
Surgery + chemotherapy (na)
Surgery + chemotherapy + tamoxifen (na) / Any-site (439) / At baseline,
original study data formd, height and weight measuredd / Not stated
Contralateral Breast (242; premenopausal, 156; postmenopausal, 86)
Trentham-Dietz,2007 / United States,
1987-2000 / 10953
(White, 95) / 59 / 7 / Stage: local (63), regional (28.9), distant (2.3), unknown (5.8)
LN: na
ER: na
PR: na / na / Breast (351)f / At baseline,
phone interview with a questionnaireg, height and weight self-reported /  12 months (Wisconsin tumor registry), ipsilateral if different histologic types and  12 mo
Endometrial (90)
Ovarian (28)
Colorectal (127)
Majed, 2009 / France,
1981-1999 / 14709
(na) / 54d / 8 / Stage: I (46), II (46.2), III (7.8)
LN: N0-N1a (84.1), N1b-N3 (15.9)
ER: + (47.4), - (18.5), na (34.1)
PR: + (46.5), - (24.8), na (28.7) / Surgery (88.3)
Hormonotherapy (29.1)
Chemotherapy (29.5)
Radiotherapy (80.6) / Contralateral Breast (1009) / At baseline,
medical record, height and weight measuredd / None, confirmation by an anatomo-pathologist
Othersh (555)
BMI, body mass index; na, not available.
aFirst tumor stage, lymph node (LN)status, estrogen receptor (ER) status, progesterone receptor (PR) status.
bOnly second primary cancer sites for which at least three BMI categories are available.
cMinimal time between the 2 diagnoses imposed by the investigators to identify second primary cancers.
dPersonal communication from the authors.
e37different anatomic sites after exclusion of contralateral breast and endometrial second primary cancers.
fSecond primary breast cancers including both contralateral and ipsilateral second breast cancers.
gPhone interviews were conducted approximately 1 year after the first diagnosis.
hGynecological, digestive and other second primary cancers.

- 1 -